CoChat

Depression and Anxiety in Individuals with Amyotrophic Lateral Sclerosis: Epidemiology and Management

Kurt, Anja, Nijboer, Femke, Matuz, Tamara, K??bler, Andrea · 2007 · CNS Drugs

The DOI matches its Crossref record, with a small difference in title or year; 63 of the 63 references it cites were found in a registry or an index.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease with no curative treatment. Considering the devastating nature of the disease, a high prevalence of depression and anxiety in affected patients would be expected. A review of the literature shows prevalence rates for depression in ALS patients ranging from 0% to 44%, but studies using the structured interview according to DSM-IV criteria find highly consistent rates of 9-11%. Prevalence rates for anxiety in ALS range from 0% to 30%. Depression and anxiety appear to be not always properly addressed aspects of ALS, as there are only a few references in the literature about psychological and pharmacological interventions. Additionally, pharmacological antidepressant therapy is often not continuously monitored and its effectiveness remains unevaluated. A review of the literature and our own experiences show that there is a lack of psychological care and, to our knowledge, there is no specific psychological intervention method for ALS patients. Concerning pharmacological treatment of depression in patients with ALS, there is broad consensus among clinical experts that SSRIs and TCAs are helpful, but there have been no controlled clinical studies of these medications in ALS patients. TCAs can be prescribed if anticholinergic effects are desired simultaneously for treating pseudohypersalivation or insomnia. Anxiety is usually treated with anxiolytics, but again there have been no systematic studies of these drugs in patients with ALS. For psychological intervention we suggest a cognitive behavioural approach, which has to be integrated into an intervention programme that includes teaching of appropriate coping strategies and reappraisal skills and encourages engagement in activities that are still practicable and pleasant. We propose that the treatment of depression and anxiety should involve both cognitive behavioural therapy and pharmacological intervention. Pharmacological treatment should be strictly monitored for effectiveness. To date, no clinical trials are available that would allow us to recommend pharmacotherapy over psychotherapy or vice versa; however, evidence from other patient groups, such as elderly patients diagnosed with major depressive disorder, suggests that a combination of both therapies has the potential to also improve depression and anxiety in patients with ALS.

Overview

Integrity signals

Registry

Crossref · 10.2165/00023210-200721040-00003

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 63 references

Cited by

See all 177

Metadata

Authors
Kurt, A., Nijboer, F., Matuz, T., & K??bler, A.
Affiliations
  • Universität Ulm (DE)
  • University of Tübingen (DE)
Venue
CNS Drugs
Published
2007
Volume
21
Issue
4
Pages
279-291
ISSN
1172-7047 (ISSN-L)
OpenAlex
W2083316633
Cited by
177
References
63
Citations by year
2026: 6 · 2025: 9 · 2024: 12 · 2023: 10 · 2022: 9 · 2021: 13 · 2020: 7 · 2019: 13 · 2018: 15 · 2017: 7 · 2016: 10 · 2015: 12 · 2014: 5 · 2013: 2 · 2012: 8
FWCI
5.32
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
amyotrophic lateral sclerosis, depression, anxiety, prevalence, antidepressant treatment, selective serotonin reuptake inhibitors, tricyclic antidepressants, anxiolytics, cognitive behavioral therapy, psychological intervention, coping strategies, motor neuron disease
MeSH terms
Amyotrophic Lateral Sclerosis, Anxiety, Depression, Humans, Male, Middle Aged

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Depression and Anxiety in Individuals with Amyotrophic Lateral Sclerosis: Epidemiology and Management. https://app.cochat.ai/papers/10.2165/00023210-200721040-00003
The paper
Kurt, A., Nijboer, F., Matuz, T., & K??bler, A. (2007). Depression and Anxiety in Individuals with Amyotrophic Lateral Sclerosis: Epidemiology and Management. CNS Drugs. https://doi.org/10.2165/00023210-200721040-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.